Highlights BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Market Closed - Canadian Securities Exchange Other stock markets 03:47:05 2024-04-29 pm EDT			5-day change	1st Jan Change
0.075 ^CAD	0.00%		-11.76%	+50.00%

Apr. 10	Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	CI
Apr. 03	BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	Apr. 10	CI
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	Apr. 03	CI
BioVaxys Technology Plans Private Placement; Down 5.9%	Mar. 25	MT
BioVaxys Technology Corp. Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications	Mar. 05	CI
Biovaxys Completes The Acquisition Of All Intellectual Property And Clinical Stage Assets Of The Former IMV Inc.	Feb. 21	MT
BioVaxys Acquires Entire Technology Portfolio Of The Former IMV Inc.	Feb. 12	MT
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Buy; Comes After BioVaxys and Procare Health Agreed to Terminate USA Distribution Agreement for Papilocare	Dec. 22	MT
BioVaxys Technology Corp. and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare and Immunocaps	Dec. 20	CI
BioVaxys Technology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	Nov. 14	CI
BioVaxys Technology Corp. and The Ohio State University Extend Research Collaboration	23-08-28	CI
BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-29	CI
10402588 BC Ltd acquired TAETSoftware Corp.	23-06-12	CI
BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-29	CI
BioVaxys Technology Corp. acquired TAETSoftware Corp for CAD 1.9 million.	23-03-15	CI
BioVaxys Technology Corp. Reports Earnings Results for the Full Year Ended October 31, 2022	23-03-03	CI
BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps	22-12-19	CI
BioVaxys Technology Corp. Announces Results from the Ohio State University Pan-Sarbecovirus Animal Study	22-12-16	CI
BioVaxys Announces Successful Test-Run Production of Its Bi-Haptenized Ovarian Cancer Vaccine	22-12-01	CI
BioVaxys' Sarbecovirus Vaccine Interim Data Show "Excellent" Emerging Safety & Tolerability Profile with BVX-1021	22-11-16	MT
Biovaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021	22-11-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Highlights

Filters